Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.

The American journal of clinical nutrition - 1 May 2010

Vernarelli Jacqueline A, Roberts J Scott, Hiraki Susan, Chen Clara A, Cupples L Adrienne, Green Robert C

Abstract excerpt

BACKGROUND: Genetic susceptibility testing for Alzheimer disease (AD) with APOE genotype disclosure is not recommended for clinical use but is available through direct-to-consumer (DTC) genetic testing companies. Little is known about whether APOE genotype disclosure would actually prompt changes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Apolipoprotein E4
Share to Black People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dietary Supplements

Share to Educational Status

Share to Family

Share to Random Allocation

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 20219963
DOI: 10.3945/ajcn.2009.28981
PMCID: PMC2854909

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20219963-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of Alzheimer disease genetic risk disclosure on dietary supplement use.PMID 20219963Read ↗

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.Semantic proximity Read ↗

Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates.Semantic proximity Read ↗

Disclosure of APOE genotype for risk of Alzheimer's disease.Semantic proximity Read ↗

Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study.Semantic proximity Read ↗

Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.Semantic proximity Read ↗

Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.Semantic proximity Read ↗

Impact of genetic risk assessment on nutrition-related lifestyle behaviours.Semantic proximity Read ↗

Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics.Semantic proximity Read ↗

A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone.Semantic proximity Read ↗

The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study.Semantic proximity Read ↗

Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease.Semantic proximity Read ↗

The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.